Levi & Korsinsky, LLP encourages investors who suffered losses in Grail, Inc. (NASDAQ: GRAL) to contact the firm. Those who ...
Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...
A gravitational-wave signal detected last November — one with properties that no known stellar physics can account for — has just received its most rigorous scientific treatment yet. A peer-reviewed ...
Spruce Biosciences offers a high-risk, high-reward opportunity as it advances TA-ERT, potentially the first disease-modifying therapy for MPS IIIB, toward FDA approval. TA-ERT demonstrated durable ...
Biography.com on MSN
The Surprising Reason the British Failed to Capture Washington During the Revolution
The fate of the leader of the Continental Army and the American Revolution were on the line in 1780.
Background Rheumatic heart disease (RHD) remains a major cause of morbidity and mortality in low-resource settings, ...
Early-stage financing rounds are on track to hit their lowest dollar value in years as funders continue to eschew risky investments, experts told BioSpace. In the first half of 2026, the major theme ...
Zacks Small Cap Research on MSN
OTC Markets Life Sciences Investor Forum: Stacy Lindborg, PhD, President, CEO, and Board Director, of Imunon with Zacks SCR’s David Bautz, PhD
NASDAQ: IMNN Host: Hello and welcome to the Life Sciences Investor Forum. On behalf of OTC Markets and our co-host, Zacks Small Cap Research, we are very pleased you've joined us. The next ...
Sellas Life Sciences stock faces downside risk ahead of REGAL Phase 3 data, and the valuation looks stretched. Click here to ...
The aim of the case studies below is to help in think through some past experiences of governments and reform, as governments, countries, and people face the future. The examples discussed are not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results